Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 17, 2017

Deals this week: Alnylam Pharmaceuticals, Myovant Sciences, Denali Therapeutics

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125 a share.

Alnylam Pharmaceuticals plans to raise $700m through a public offering of five million shares of its common stock priced at $125 a share.

The US-based ribonucleaic acid interference (RNAi) therapeutics company plans to use the funds for general corporate purposes, as well as research and development (R&D) activities.

Myovant Sciences plans to issue securities to raise $300m.

The securities include common shares, preference shares, debt securities, and warrants.

The company plans to use the proceeds towards clinical development programmes for relugolix and for general corporate purposes.

Denali Therapeutics plans to raise $100m through an initial public offering (IPO) of shares of its common stock.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
“Odonate Therapeutics plans to raise $172.5m through an initial public offering (IPO) of shares of its common stock.”

The US-based neurodegenerative diseases company intends to use the funds towards Phase I and II trials and general corporate purposes.

Arcus Biosciences Inc has secured $107m in a series C funding round led by GV.

Formerly known as Google Ventures, this US-based biotechnology company plans to use the funds to progress the clinical programmes for AB928.

Odonate Therapeutics plans to raise $172.5m through an initial public offering (IPO) of shares of its common stock.

The US-based discovery-stage company plans to use the funds towards clinical studies of tesetaxel and general corporate purposes.

Sage Therapeutics plans to issue a public offering of three million shares of its common stock priced at $85 a share to raise $300m.

The US-based clinical-stage biopharmaceutical company plans to use the funds for new drug application (NDA) submission of brexanolone and general corporate purposes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU